DepoMed Beats on Both Top and Bottom Lines
DepoMed (NAS: DEPO) reported earnings on Nov. 5. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), DepoMed beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share contracted.
Margins increased across the board.
DepoMed logged revenue of $33.3 million. The four analysts polled by S&P Capital IQ wanted to see revenue of $28.1 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $16.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The three earnings estimates compiled by S&P Capital IQ forecast -$0.11 per share. GAAP EPS were -$0.03 for Q3 versus -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.7%, 170 basis points better than the prior-year quarter. Operating margin was -4.6%, 5,170 basis points better than the prior-year quarter. Net margin was -4.5%, 4,740 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $25.6 million. On the bottom line, the average EPS estimate is -$0.12.
Next year's average estimate for revenue is $84.7 million. The average EPS estimate is -$0.67.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 231 members out of 246 rating the stock outperform, and 15 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give DepoMed a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.38.
- Add DepoMed to My Watchlist.
The article DepoMed Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.